SCHEMBL10126577

SCHEMBL10126577

CSc1nc(Cl)c(C(N)=O)c(Nc2cc(S(=O)(=O)N3CCCCC3)ccc2F)n1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.44
GAA P10253 2/20 0.44
HTT P42858 2/20 0.44
KDM4E B2RXH2 1/20 0.44
CYP3A4 P08684 1/20 0.42
ALDH1A1 P00352 2/20 0.41
LMNA P02545 6/20 0.41
TP53 P04637 2/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PKM P14618 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
MITF O75030 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
UBE2N P61088 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10126471 0.91 HTT (0.49) MAPTGAAHTTKDM4EALDH1A1
SCHEMBL10126576 0.82 CYP3A4 (0.41) MAPTGAAHTTKDM4ECYP3A4
SCHEMBL10126528 0.79 MAPT (0.43) MAPTHTTALDH1A1LMNATP53
SCHEMBL10157042 0.76 MCOLN3 (0.44) MAPTGAAKDM4EALDH1A1LMNA
SCHEMBL10126552 0.75 IRAK4 (0.42) MAPTHTTKDM4EALDH1A1LMNA
SCHEMBL10126504 0.74 TNNI3K (0.46) MAPTGAALMNA
SCHEMBL10126469 0.74 ALDH1A1 (0.46) MAPTHTTKDM4EALDH1A1LMNA
SCHEMBL10126496 0.73 CA1 (0.39) MAPTGAAALDH1A1TP53L3MBTL1
SCHEMBL10126449 0.73 HPGD (0.42) MAPTTSHRKMT2AMEN1
SCHEMBL10128668 0.72 SYK (0.53) MAPTGAAKDM4ECYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 MAPT 3116/4885GAA 3821/4885HTT 3739/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 MAPT 3116/4885GAA 3821/4885HTT 3739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.